Spherix Global Insights

December 09, 2021

Report: Tecfidera, Aubagio Preferred RRMS Treatments in Canada

From: Multiple Sclerosis News Today

By: Marisa Wexler MS

Multiple Sclerosis News Today | Symptoms, Diagnosis, Treatments

 

Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments for managing relapsing-remitting multiple sclerosis (RRMS) in Canada, according to a report from Spherix Global Insights.

The report was part of Spherix’s RealTime Dynamix: Multiple Sclerosis (Canada) service, which collects data on market trends of MS treatments in Canada by surveying healthcare providers in the country. This most recent report is based on responses from 47 MS specialists and neurologists, given in October and early November.

The preference for Tecfidera and Aubagio as a first-line RRMS treatment, “is easily seen in the strong reliance on these brands for first-line RRMS prescribing, especially among patients presenting without concerning prognostic profiles,” according to a press release from Spherix… (read more)